ロード中...
Lenvatinib and radioiodine-refractory thyroid cancers
Over the past decade, several multikinase inhibitors have shown considerable effectiveness against metastatic radioiodine-refractory thyroid cancers in early stage clinical trials. On the basis of some remarkable results in a phase III clinical trial, lenvatinib now joins sorafenib as another multik...
保存先:
| 出版年: | Nat Rev Endocrinol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4518863/ https://ncbi.nlm.nih.gov/pubmed/25824678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrendo.2015.53 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|